Effectiveness of A(H1N1)pdm09 influenza vaccine in adults recommended for annual influenza vaccination

Giedre Gefenaite*, Margot Tacken, Jens Bos, Irina Stirbu-Wagner, Joke C. Korevaar, Ronald P. Stolk, Bert Wolters, Marc Bijl, Maarten J. Postma, Jan Wilschut, Kristin L. Nichol, Eelko Hak

*Bijbehorende auteur voor dit werk

    OnderzoeksoutputAcademicpeer review

    6 Citaten (Scopus)
    208 Downloads (Pure)

    Samenvatting

    INTRODUCTION: Because of variability in published A(H1N1)pdm09 influenza vaccine effectiveness estimates, we conducted a study in the adults belonging to the risk groups to assess the A(H1N1)pdm09 MF59-adjuvanted influenza vaccine effectiveness.

    METHODS: VE against influenza and/or pneumonia was assessed in the cohort study (n>25000), and vaccine effectiveness against laboratory-confirmed A(H1N1)pdm09 influenza was assessed in a matched case-control study (16 pairs). Odds ratios (OR) and their 95% confidence intervals (95% CI) were calculated by using multivariate logistic regression; vaccine effectiveness was estimated as (1-odds ratio)*100%.

    RESULTS: Vaccine effectiveness against laboratory-confirmed A(H1N1)pdm09 influenza and influenza and/or pneumonia was 98% (84-100%) and 33% (2-54%) respectively. The vaccine did not prevent influenza and/or pneumonia in 18-59 years old subjects, and was 49% (16-69%) effective in 60 years and older subjects.

    CONCLUSIONS: Even though we cannot entirely rule out that selection bias, residual confounding and/or cross-protection has played a role, the present results indicate that the MF59-adjuvanted A(H1N1)pdm09 influenza vaccine has been effective in preventing laboratory-confirmed A(H1N1)pdm09 influenza and influenza and/or pneumonia, the latter notably in 60 years and older subjects.

    Originele taal-2English
    Artikelnummere66125
    Aantal pagina's6
    TijdschriftPLoS ONE
    Volume8
    Nummer van het tijdschrift6
    DOI's
    StatusPublished - 20-jun-2013

    Citeer dit